569 related articles for article (PubMed ID: 26496556)
21. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
[TBL] [Abstract][Full Text] [Related]
22. Minimum apparent diffusion coefficients in the evaluation of brain tumors.
Kitis O; Altay H; Calli C; Yunten N; Akalin T; Yurtseven T
Eur J Radiol; 2005 Sep; 55(3):393-400. PubMed ID: 16129247
[TBL] [Abstract][Full Text] [Related]
23. Grading Gliomas Capability: Comparison between Visual Assessment and Apparent Diffusion Coefficient (ADC) Value Measurement on Diffusion-Weighted Imaging (DWI).
Phuttharak W; Thammaroj J; Wara-Asawapati S; Panpeng K
Asian Pac J Cancer Prev; 2020 Feb; 21(2):385-390. PubMed ID: 32102515
[TBL] [Abstract][Full Text] [Related]
24. Diffusional kurtosis imaging for differentiating between high-grade glioma and primary central nervous system lymphoma.
Pang H; Ren Y; Dang X; Feng X; Yao Z; Wu J; Yao C; Di N; Ghinda DC; Zhang Y
J Magn Reson Imaging; 2016 Jul; 44(1):30-40. PubMed ID: 26588793
[TBL] [Abstract][Full Text] [Related]
25. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.
Choi HS; Kim AH; Ahn SS; Shin NY; Kim J; Lee SK
Korean J Radiol; 2013; 14(3):487-92. PubMed ID: 23690718
[TBL] [Abstract][Full Text] [Related]
26. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance of advanced MRI in differentiating high-grade from low-grade gliomas in a setting of routine service.
Chawalparit O; Sangruchi T; Witthiwej T; Sathornsumetee S; Tritrakarn S; Piyapittayanan S; Chaicharoen P; Direksunthorn T; Charnchaowanish P
J Med Assoc Thai; 2013 Oct; 96(10):1365-73. PubMed ID: 24350420
[TBL] [Abstract][Full Text] [Related]
28. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?
Jain R; Ellika S; Lehman NL; Scarpace L; Schultz LR; Rock JP; Rosenblum M; Mikkelsen T
J Neurooncol; 2010 May; 97(3):383-8. PubMed ID: 19830525
[TBL] [Abstract][Full Text] [Related]
29. Perfusion Imaging of Tumefactive Demyelinating Lesions Compared to High Grade Gliomas.
Parks NE; Bhan V; Shankar JJ
Can J Neurol Sci; 2016 Mar; 43(2):316-8. PubMed ID: 26573406
[No Abstract] [Full Text] [Related]
30. Glioma grading using apparent diffusion coefficient map: application of histogram analysis based on automatic segmentation.
Lee J; Choi SH; Kim JH; Sohn CH; Lee S; Jeong J
NMR Biomed; 2014 Sep; 27(9):1046-52. PubMed ID: 25042540
[TBL] [Abstract][Full Text] [Related]
31. Differentiating Primary Central Nervous System Lymphomas From Glioblastomas and Inflammatory Demyelinating Pseudotumor Using Relative Minimum Apparent Diffusion Coefficients.
Wen JB; Huang WY; Xu WX; Wu G; Geng DY; Yin B
J Comput Assist Tomogr; 2017; 41(6):904-909. PubMed ID: 28708728
[TBL] [Abstract][Full Text] [Related]
32. Neuroimaging and clinicopathological differences between tumefactive demyelinating lesions and sentinel lesions of primary central nervous system lymphoma.
Sun C; Han J; Lin Y; Qi X; Li C; Liu J; Qiu F
Front Immunol; 2022; 13():986473. PubMed ID: 36059526
[TBL] [Abstract][Full Text] [Related]
33. Tumefactive demyelinating lesions versus CNS neoplasms, a comparative study.
Chew SH; Achmad Sankala HB; Chew E; Md Arif MHB; Mohd Zain NR; Hashim H; Koya Kutty SB; Chee YC; Mohd Saleh NB; Ong BH; Viswanathan S
Mult Scler Relat Disord; 2023 Nov; 79():104992. PubMed ID: 37717306
[TBL] [Abstract][Full Text] [Related]
34. Differentiating between Glioblastoma and Primary CNS Lymphoma Using Combined Whole-tumor Histogram Analysis of the Normalized Cerebral Blood Volume and the Apparent Diffusion Coefficient.
Bao S; Watanabe Y; Takahashi H; Tanaka H; Arisawa A; Matsuo C; Wu R; Fujimoto Y; Tomiyama N
Magn Reson Med Sci; 2019 Jan; 18(1):53-61. PubMed ID: 29848919
[TBL] [Abstract][Full Text] [Related]
35. Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI.
Chang SC; Lai PH; Chen WL; Weng HH; Ho JT; Wang JS; Chang CY; Pan HB; Yang CF
Clin Imaging; 2002; 26(4):227-36. PubMed ID: 12140151
[TBL] [Abstract][Full Text] [Related]
36. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastases using susceptibility-weighted imaging.
Ding Y; Xing Z; Liu B; Lin X; Cao D
Brain Behav; 2014; 4(6):841-9. PubMed ID: 25365807
[TBL] [Abstract][Full Text] [Related]
37. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
Saini J; Chatterjee S; Thomas B; Kesavadas C
Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
[TBL] [Abstract][Full Text] [Related]
38. Intravoxel incoherent motion diffusion-weighted MR imaging of gliomas: efficacy in preoperative grading.
Hu YC; Yan LF; Wu L; Du P; Chen BY; Wang L; Wang SM; Han Y; Tian Q; Yu Y; Xu TY; Wang W; Cui GB
Sci Rep; 2014 Dec; 4():7208. PubMed ID: 25434593
[TBL] [Abstract][Full Text] [Related]
39. In the assessment of supratentorial glioma grade: the combined role of multivoxel proton MR spectroscopy and diffusion tensor imaging.
Zou QG; Xu HB; Liu F; Guo W; Kong XC; Wu Y
Clin Radiol; 2011 Oct; 66(10):953-60. PubMed ID: 21663899
[TBL] [Abstract][Full Text] [Related]
40. Tumefactive Multiple Sclerosis Masquerading as High Grade Glioma.
Lin M; Reid P; Bakhsheshian J
World Neurosurg; 2018 Apr; 112():37-38. PubMed ID: 29331745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
